- January 22, 2025CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…
- January 22, 2025Be sure to catch up on the latest happenings in our winter newsletter here!
- November 25, 2024- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown…
- November 25, 2024− Prescription Drug User Fee Act (PDUFA) Date Set for March 23, 2025 − CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 25, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY),…
- November 18, 2024CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…
- September 25, 2024Be sure to catch up on the latest happenings in our fall newsletter here!
- August 30, 2024CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B…
- June 25, 2024CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 24, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive topline results from its…
- April 23, 2024Catch up on the latest happenings in our spring newsletter here!
- January 18, 2024Explore the most recent updates in the 2024 Winter Newsletter.
7151 N. Main St. Ste. 2 Clarkston, MI 48346
248-922-9610